Search results for

As part of its bid to enter the WTO, Vietnam has consolidated its confusing maze of IP rules and regulations into a streamlined law that comes into force in the middle of the year. Chris Vale examines what the changes mean for IP owners

Sorting out who owns what in when a licensing partner goes bust can be a tricky business. Andrew Jones of Sim Lowman Ashton & McKay looks at cases that have shaped the rights and obligations of parties in such cases

Opposition proceedings were introduced into Canada's trade mark legislation just over 50 years ago. While the opposition process functioned relatively well for the first few decades, such has not been the case recently. Gary Partington and Coleen Morrison of Marks & Clerk examine what changes lie ahead

A number of pivotal copyright decisions were handed down last year, establishing precedent-setting rules for rights owners in Canada, says Brian W Gray of McCarthy Tétrault

A series of recent decisions in Canada and the UK has established rules for the way courts interpret patent claims. Robert H C MacFarlane and Adam Bobker of Bereskin & Parr explain what the changes mean for rights owners

Owning a market-leading product or innovation is useless if you fail to keep your competitors from copying you. Daniel S Drapeau and George R Locke of Ogilvy Renault outline the most effective options available to rights owners

With discussions on the accession to the European Union and global harmonization of IP protection in an emerging economy, Turkey has experienced remarkable advances not only in the new regulations introduced but also in the enforcement of IP rights.

Following a period of calm, Russian law has again made a slight move towards better protection of the owners of IP rights. The major changes in the IP-specific laws were made in late 2002/early 2003. Since then, amendments have occasionally been made to the non-specific laws, such as the Criminal Code.

With the publication of mailbox patent applications in the Official Gazette, a fierce battle has erupted between Indian and multinational pharmaceutical companies. According to media reports, Indian drug companies including Cipla, Ranbaxy and Cadila have filed around 45 pre-grant oppositions in the form of representations with the Controller of Patents. Major targets include Novartis' anti-asthma molecule, Pfizer's new controlled use of a known molecule and Scherring's formulation for PEG Interferon Alpha conjugates.

In less than six months Germany will host the 18th tournament of the FIFA World Cup, attracting thousands of visitors eager to support their favourite football team. Marketing opportunities will be plenty. But what legal protection will Germany offer to official sponsors to protect them against the marketing practices of unofficial third parties? Boris Uphoff, Rohan Massey and Sarah Brown explain